genOway SA engages in the development of genetically-modified mouse, rat, and cellular models for biopharmaceutical and research companies. Its technologies include CRISPR/Cas9, homologous recombination (HR), site-specific recombination (SSR), internal ribosome entry sites (IRES), and tetracycline (TET). The company was founded by Alexandre Fraichard and Gilles de Poncins on March 1, 1999 and is headquartered in Lyon, France.